We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
Black People
/ statistics & numerical data
Cholangitis, Sclerosing
/ epidemiology
Ethnic and Racial Minorities
/ statistics & numerical data
Health Inequities
Health Services Accessibility
Health Services Needs and Demand
Hepatitis, Autoimmune
/ epidemiology
Hispanic or Latino
/ statistics & numerical data
Humans
Liver
/ immunology
Social Determinants of Health
/ statistics & numerical data
United States
/ epidemiology
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
29
04
2021
received:
29
11
2020
accepted:
25
05
2021
pubmed:
1
6
2021
medline:
14
1
2022
entrez:
31
5
2021
Statut:
ppublish
Résumé
Autoimmune liver diseases are attributed to a complex interplay of biologic, acquired, and environmental factors. Increased prevalence, later stage at presentation, worse response to standard therapy, and transplant-related disparities have all been reported in racial and ethnic minorities such as Black and Latinx patients with autoimmune liver diseases. While biology and inherited genetic predispositions may partly explain these disparities, definitive and universal genetic variations underlying these differences in outcomes have not been defined. Nonetheless, socioeconomic status, access to health care, environmental and societal factors, and implicit provider bias can all contribute to poor patient outcomes. There remains an unmet need to understand and mitigate the factors contributing to health inequity in autoimmune liver diseases. In this review, we summarize the data on racial and ethnic disparities in presentation, treatment response, and outcomes pertaining to autoimmune liver diseases in minority populations, on the premise that understanding disparities is the first step toward reaching health equity.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2876-2887Informations de copyright
© 2021 by the American Association for the Study of Liver Diseases.
Références
Grief SN, Miller JP. Infectious disease issues in underserved populations. Prim Care 2017;44:67-85.
Hall WJ, Chapman MV, Lee KM, Merino YM, Thomas TW, Payne BK, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health 2015;105:e60-e76.
Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2019;17:551-559.e1.
Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:198-210.e2.
Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011;53:1839-1845.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394-419.
Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 2013;7:365-385.
Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643.
Levy C, Naik J, Giordano C, Mandalia A, O'Brien C, Bhamidimarri KR, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol 2014;12:1398-1405.
Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007;46:769-775.
Centers for Disease Control and Prevention. About social determinants of health (SDOH). https://www.cdc.gov/socialdeterminants/about.html. Published March 10, 2021. Accessed February 26, 2021.
Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol 2018;16:1342-1350.e1.
Galoosian A, Hanlon C, Tana M, Cheung R, Wong RJ. Race/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007-2014 national inpatient sample. Dig Dis Sci 2020;65:406-415.
Adejumo AC, Akhtar DH, Dennis BB, Cholankeril G, Alayo Q, Ogundipe OA, et al. Gender and racial differences in hospitalizations for primary biliary cholangitis in the USA. Dig Dis Sci 2021;66:1461-1476.
Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM, et al. Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol Commun 2019;3:356-364.
Sayiner M, Golabi P, Stepanova M, Younossi I, Nader F, Racila A, et al. Primary biliary cholangitis in Medicare population: the impact on mortality and resource use. Hepatology 2019;69:237-244.
Lu M, Li J, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol 2018;16:1333-1341.e6.
Gordon SC, Wu K-H, Lindor K, Bowlus CL, Rodriguez CV, Anderson H, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. Am J Gastroenterol 2020;115:262-270.
Rabiee A, Polanco NAP, Vara AFDL, Levy C. Hispanic patients with primary biliary cholangitis have decreased access to care compared to non-Hispanics. J Clin Transl Hepatol 2020;8:391-396.
Rieger R, Gershwin ME. The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007;28:76-84.
Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980;281:772-775.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-1202.
Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, et al. Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites. Hepatology 2006;43:525-531.
Dyson JK, Blain A, Foster Shirley MD, Hudson M, Rushton S, Jeffreys Jones DE. Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Rep 2021;3:100202.
Cholankeril G, Gonzalez HC, Satapathy SK, Gonzalez SA, Hu M, Khan MA, et al. Increased waitlist mortality and lower rate for liver transplantation in Hispanic patients with primary biliary cholangitis. Clin Gastroenterol Hepatol 2018;16:965-973.e2.
Farrell GC. Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. J Gastroenterol Hepatol 2008;23:508-511.
Zeng NA, Duan W, Chen S, Wu S, Ma H, Ou X, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int 2019;13:788-799.
Lin C-Y, Cheng Y-T, Chang M-L, Chien R-N. The extrahepatic events of Asian patients with primary biliary cholangitis: a 30-year cohort study. Sci Rep 2019;9:7577.
Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int 2016;10:909-915.
Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402-2407.
Kerkar N. Autoimmune hepatitis in special populations: in pediatrics and across different ethnicities/races. Clin Liver Dis 2019;14:37-40.
Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-706.
Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-2035.
Ngu JH, Gearry RB, Frampton CM, Stedman CAM. Autoimmune hepatitis: the role of environmental risk factors: a population-based study. Hepatol Int 2013;7:869-875.
Lee B, Holt EW, Wong RJ, Sewell JL, Somsouk MA, Khalili M, et al. Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved. Autoimmunity 2018;51:258-264.
Wen JW, Kohn MA, Wong R, Somsouk MA, Khalili M, Maher J, et al. Hospitalizations for autoimmune hepatitis disproportionately affect Black and Latino Americans. Am J Gastroenterol 2018;113:243-253.
Thuluvath PJ, Wagennar RR, Verma S. Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Arch Med Sci 2015;11:1227-1235.
Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713-717.
Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007;46:1828-1835.
Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001;96:3390-3394.
Palle SK, Naik KB, McCracken CE, Kolachala VL, Romero R, Gupta NA. Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. Liver Int 2019;39:976-984.
de Boer YS, Gerussi A, van den Brand FF, Wong GW, Halliday N, Liberal R, et al. Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2019;17:1616-1624.e2.
Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. Clin Gastroenterol Hepatol 2018;16:278-287.7.
Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS liver transplant registry. Clin Transpl 2004:315-329.
Nephew L, Zia Z, Ghabril M, Orman E, Lammert C, Chalasani N. Black adult patients with acute liver failure are sicker and more likely to undergo liver transplantation than White patients. Liver Transpl 2019;25:1634-1641.
Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012;46:155-161.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-1507.
Vázquez-García MN, Aláez C, Olivo A, Debaz H, Pérez-Luque E, Burguete A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-990.
Zahiruddin A, Farahmand A, Gaglio P, Massoumi H. Clinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population. Gastroenterol Hepatol Bed Bench 2016;9:225-230.
Lee BT, Wang Y, Yuan L, Han H, Donovan JA, Kahn J, et al. High prevalence of overlap syndrome of primary biliary cholangitis and autoimmune hepatitis and association with advanced fibrosis in Hispanic patients in Los Angeles. Hepatology 2017;66(Suppl. 1):149-1185.
Martínez LA, Larrieta E, Calva JJ, Kershenobich D, Torre A. The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in Hispanic population. Ann Hepatol 2017;16:909-915.
Goran MI, Walker R, Le K-A, Mahurkar S, Vikman S, Davis JN, et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010;59:3127-3130.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
Mederacke YS, Kirstein MM, Großhennig A, Marhenke S, Metzler F, Manns MP, et al. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1160-1168.
Fainboim L, Cañero Velasco MC, Marcos CY, Ciocca M, Roy A, Theiler G, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-1517.
Enomoto H, Nishiguchi S. Similarities and differences in autoimmune hepatitis epidemiology between East and West: autoimmune hepatitis in East Asia, Southeast Asia, and South Asia. Inflamm Intest Dis 2017;1:150-158.
Chung HV, Riley M, Ho JK, Leung B, Jevon GP, Arbour LT, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol 2007;21:565-568.
Minuk GY, Liu S, Kaita K, Wong S, Renner E, Rempel J, et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008;22:829-834.
Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, et al. Primary sclerosing cholangitis is not rare among blacks in a multicenter North American consortium. Clin Gastroenterol Hepatol 2018;16:591-593.
Bowlus CL, Li C-S, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl 2010;16:1324-1330.
Trivedi PJ, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 2020;159:915-928.
Nobel YR, Forde KA, Wood L, Cartiera K, Munoz-Abraham AS, Yoo PS, et al. Racial and ethnic disparities in access to and utilization of living donor liver transplants. Liver Transpl 2015;21:904-913.
Lee BT, Wang Y, Yang A, Han H, Yuan L, Donovan J, et al. IgG:IgM ratios of liver plasma cells reveal similar phenotypes of primary biliary cholangitis with and without features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2019;19:397-399.
US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Healthy People 2030. https://health.gov/healthypeople. Accessed February 26, 2021.
Biener AI, Zuvekas SH. Do racial and ethnic disparities in health care use vary with health? Health Serv Res 2019;54:64-74.
Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology 2008;47:1058-1066.
Fleming PJ, Novak NL, Lopez WDUS. Immigration law enforcement practices and health inequities. Am J Prev Med 2019;57:858-861.
George S, Hamilton A, Baker RS. How do low-income urban African Americans and Latinos feel about telemedicine? A diffusion of innovation analysis. Int J Telemed Appl 2012;2012:715194.
Kim D, Eshtiaghpour D, Alpern J, Datta A, Eysselein VE, Yee HF. Access to primary care is associated with better autoimmune hepatitis outcomes in an urban county hospital. BMC Gastroenterol 2015;15:91.
Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
Aronson J, Burgess D, Phelan SM, Juarez L. Unhealthy interactions: the role of stereotype threat in health disparities. Am J Public Health 2013;103:50-56.
Steinberg EM, Valenzuela-Araujo D, Zickafoose JS, Kieffer E, DeCamp LR. The “battle” of managing language barriers in health care. Clin Pediatr 2016;55:1318-1327.
Shen MJ, Peterson EB, Costas-Muñiz R, Hernandez MH, Jewell ST, Matsoukas K, et al. The effects of race and racial concordance on patient-physician communication: a systematic review of the literature. J Racial Ethn Health Disparities 2018;5:117-140.
Saha S, Shipman SA. Race-neutral versus race-conscious workforce policy to improve access to care. Health Aff 2008;27:234-245.
AASLD statement on diversity and call to action. https://www.aasld.org/membership/member-resources/member-committees/aasld-statement-diversity-and-call-action. Accessed February 26, 2021.
Kim KA, Kim YS, Park SH, Chung WJ, Choi DH, Jang ES, et al. Environmental risk factors and comorbidities of primary biliary cholangitis in Korea: a case-control study. Korean J Intern Med 2020;36:313.
Shaheen A-A, Kaplan GG, Almishri W, Vallerand I, Frolkis AD, Patten S, et al. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PLoS One 2018;13:e0194839.
Staufer K, Kivaranovic D, Rasoul-Rockenschaub S, Soliman T, Trauner M, Berlakovich G. Waitlist mortality and post-transplant survival in patients with cholestatic liver disease-impact of changes in allocation policy. HPB (Oxford) 2018;20:916-924.
Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Mousa OY, Pungpapong S, et al. Association between smoking and risk of primary biliary cholangitis: a systematic review and meta-analysis. J Gastrointestin Liver Dis 2019;28:197-203.
Mantaka A, Koulentaki M, Samonakis D, Sifaki-Pistolla D, Voumvouraki A, Tzardi M, et al. Association of smoking with liver fibrosis and mortality in primary biliary cholangitis. Eur J Gastroenterol Hepatol 2018;30:1461-1469.
Melchor-Mendoza YK, Martínez-Benítez B, Mina-Hawat A, Rodríguez-Leal G, Duque X, Moran-Villota S. Ursodeoxycholic acid therapy in patients with primary biliary cholangitis with limited liver transplantation availability. Ann Hepatol 2017;16:430-435.
Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, et al. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Sci Rep 2018;8:17452.
Tenca A, Färkkilä M, Jalanko H, Vapalahti K, Arola J, Jaakkola T, et al. Environmental risk factors of pediatric-onset primary sclerosing cholangitis and autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2016;62:437-442.
Comerford M, Fogel R, Bailey JR, Chilukuri P, Chalasani N, Lammert CS. Leveraging social networking sites for an autoimmune hepatitis genetic repository: pilot study to evaluate feasibility. J Med Internet Res 2018;20:e14.
Goet JC, Hansen BE, Tieleman M, van Hoek B, van den Berg AP, Polak WG, et al. Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study. Transpl Int 2018;31:590-599.
Lammert C, Juran BD, Schlicht E, Xie X, Atkinson EJ, de Andrade M, et al. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. Clin Gastroenterol Hepatol 2014;12:1562-1568.
van Erpecum KJ, Smits SJ, van de Meeberg PC, Linn FH, Wolfhagen FH, vanBerge-Henegouwen GP, et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996;110:1503-1506.
Schulz AJ, Kannan S, Dvonch JT, Israel BA, Allen A, James SA, et al. Social and physical environments and disparities in risk for cardiovascular disease: the Healthy Environments Partnership conceptual model. Environ Health Perspect 2005;113:1817-1825.
Committee on Educating Health Professionals to Address the Social Determinants of Health; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. A Framework for Educating Health Professionals to Address the Social Determinants of Health. Washington, DC: National Academies Press; 2016.